It is unknown why the potencies and efficacies of long-chained guanidine-type histamine H 2 -receptor (H 2 R) agonists are lower at the H 2 R of human neutrophils than at the H 2 R of the guinea pig atrium. To elucidate these differences, we analyzed fusion proteins of the human H 2 R (hH 2 R) and guinea pig H 2 R (gpH 2 R), respectively, and the short splice variant of G s␣ (G s␣S ) expressed in Sf9 cells. The potencies and efficacies of small H 2 R agonists in the GTPase assay and the potencies of antagonists at inhibiting histamine-stimulated GTP hydrolysis by hH 2 R-G s␣S and gpH 2 R-G s␣S were similar. In contrast, the potencies and efficacies of guanidines were lower at hH 2 R-G s␣S than at gpH 2 R-G s␣S . Guanidines bound to hH 2 R-G s␣S with lower affinity than to gpH 2 R-G s␣S , and high-affinity binding of guanidines at gpH 2 R-G s␣S was more resistant to disruption by GTP␥S than binding at hH 2 R-G s␣S . Molecular modeling suggested that the nonconserved Asp-271 in transmembrane domain 7 of gpH 2 R (Ala-271 in hH 2 R) confers high potency to guanidines. This hypothesis was confirmed by Ala-2713 Asp-271 mutation in hH 2 R-G s␣S . Intriguingly, the efficacies of guanidines at the Ala-2713 Asp-271 mutant and at hH 2 R/gpH 2 R chimeras were lower than at gpH 2 R. Our model suggests that a Tyr-17/Asp-271 H-bond, present only in gpH 2 R-G s␣S but not the other constructs studied, stabilizes the active guanidine-H 2 R state. Collectively, our data show 1) distinct interaction of H 2 R species isoforms with guanidines, 2) that a single amino acid in transmembrane domain 7 critically determines guanidine potency, and 3) that an interaction between transmembrane domains 1 and 7 is important for guanidine efficacy.
. H 2 R antagonists are divided into five chemical classes: imidazoles such as CIM (14), furans such as RAN (15) , thiazoles such as FAM (16), and TIO (17), piperidinomethylphenoxy derivatives such as ZOL (18), and (benzamidoalkyl)cyanoguanidines such as APT (19) (Hill et al., 1997) . H 2 R antagonists are of great importance for the treatment of gastroduodenal ulcer disease (Hill et al., 1997) . H 2 R agonists may be useful as positive inotropic drugs for the treatment of heart failure (Felix et al., 1995) , as differentiation-inducing agents in acute myelogenous leukemia (Seifert et al., 1992) , and as anti-inflammatory drugs (Burde et al., 1990) .
Guanidine-type compounds are less potent and/or efficient agonists at the H 2 R of human neutrophils than at the H 2 R of the guinea pig atrium (Burde et al., 1989 (Burde et al., , 1990 Buschauer, 1989) . Additionally, several GPCR species isoforms, including the H 3 R, differ from each other in their pharmacological properties as assessed by the analysis of recombinant GPCRs (Kopin et al., 2000; Ligneau et al., 2000; Lovenberg et al., 2000) . There are relatively few amino acid differences between hH 2 R and gpH 2 R (Gantz et al., 1991; Traiffort et al., 1995) (Fig. 2) , particularly in the established ligand-binding domains TM3 and TM5, but even a single amino acid exchange between GPCR species isoforms can strongly affect their pharmacological properties (Kopin et al., 2000; Ligneau et al., 2000) . Based on these findings, the hypothesis arose that the H 2 R exhibits species-specific pharmacological properties as well.
To test our hypothesis, we constructed fusion proteins of the hH 2 R and gpH 2 R, respectively, and G s␣S and expressed the fusion proteins in Sf9 cell membranes. GPCR-G ␣ fusion proteins ensure a defined 1:1 stoichiometry of the signaling partners and efficient coupling Milligan, 2000) . The measurement of GTP hydrolysis in GPCR-G ␣ fusion proteins is presumably the most precise method currently available for the analysis of ligand potencies and efficacies, because the GTPase assay is a steady-state method, is extremely sensitive in GPCR-G s␣ fusion proteins, assesses GPCR/G-protein coupling directly at the G-protein level, and is independent of the expression level of the components Milligan, 2000) . Finally, the analysis of H 2 R species isoforms in the same host cell membrane annihilates the impact of pharmacokinetic differences between different test systems. Here, we report that hH 2 R and gpH 2 R exhibit distinct pharmacological properties, particularly with respect to interaction with guanidines.
Experimental Procedures
Materials. The cDNA for the hH 2 R was kindly provided by Dr. I. Gantz (University of Michigan Medical School and Ann Arbor VA Medical Center, Ann Arbor, MI) (Gantz et al., 1991) . The cDNA for the gpH 2 R was kindly provided by Drs. E. Traiffort and J.-C. Schwartz (Department of Neurobiology and Pharmacology, Center Paul Broca, Institut National de la Santé et de la Recherche Médi-cale, Paris, France) (Traiffort et al., 1995) . The generation of the baculovirus encoding ␤ 2 AR-G s␣L had been described previously (Seifert et al., 1998a) . APT was synthesized as described previously (Hirschfeld et al., 1992) . IMP was prepared as described previously (Durant et al., 1978) . Guanidines 6 to 11 were synthesized as described previously (Buschauer, 1989) . Guanidines 12 and 13 (Schalkhausser, 1998) were prepared by analogy to the procedures described for guanidines 6 to 11 (Buschauer, 1989) . The structures of the synthesized compounds were confirmed by analysis (C, H, N) , 1 H NMR, and mass spectroscopy spectra. Purity of compounds was Ͼ98% as determined by high-performance liquid chromatography or capillary electrophoresis (Schuster et al., 1997) . The anti-FLAG Ig (M1 monoclonal antibody) was from Sigma (St. Louis, MO). The (Boston, MA) . All unlabeled nucleotides were from Roche (Indianapolis, IN). HIS, BET, CIM, RAN, and FAM were from Sigma. AMT, TIO, and ZOL were from Tocris Cookson (Ballwin, MO). DIM was from RBI (Natick, MA). All restriction enzymes and T4 DNA ligase were from New England Biolabs (Beverly, MA). Cloned Pfu DNA polymerase was from Stratagene (La Jolla, CA).
Construction of FLAG Epitope-and Hexahistidine-Tagged cDNA for hH 2 R-G s␣S . A DNA sequence encoding the cleavable signal peptide from influenza hemagglutinin (S) followed by the FLAG epitope (F), which is recognized by the M1 antibody, was placed 5Ј of the start codon of the hH 2 R to enhance GPCR expression and allow immunological detection. We also added a hexahistidine tag to the C terminus of hH 2 R to allow future purification and to provide additional protection against proteolysis (Seifert et al., 1998a) . The GPCR modifications were generated by sequential overlap-extension PCRs. In PCR 1A, the DNA sequence of the N-terminal portion of the hH 2 R was amplified using CMVneo-hH 2 R as template. The sense primer annealed with the first 18 bp of the 5Ј-end of the hH 2 R and included the last 18 bp of the SF in its 5Ј-extension. The antisense primer encoded the sequence GAGCTGTTGATATCCGGT-GCGGAAGTCTCTG to generate a silent mutation yielding a new EcoRV site. In PCR 1B, the DNA sequence of the C-terminal portion of the hH 2 R was amplified using CMVneo-hH 2 R as template. The sense primer encoded the sequence TTCCGCACCGGATATCAA-CAGCTCTTCTGCTGC to generate the new EcoRV site. The antisense primer encoded the five C-terminal amino acids of the hH 2 R, a hexahistidine tag, the stop codon and an XbaI site. In PCR 2, the products of PCRs 1A and 1B annealed in the region encoding the newly created EcoRV site. In PCR 2, the sense primer of PCR 1A and the antisense primer of PCR 1B were used. In this way, a fragment encoding the signal sequence, the FLAG epitope, hH 2 R cDNA with a new EcoRV site and a hexahistidine tag followed by an XbaI site was obtained. This fragment was digested with NcoI and XbaI and cloned into pGEM-3Z-SF-human formyl peptide receptor-6His digested with NcoI and XbaI. In PCR 3A, the C-terminal portion of the H 2 R was amplified using pGEM-3Z-SF-hH 2 R as template, a sense primer annealing 5Ј of the newly created EcoRV site and an antisense primer annealing with the hexahistidine tag. In PCR 3B, the sequence of G s␣S was amplified, using pGEM-3Z-SF-␤ 2 AR-G s␣S as template, a sense primer annealing with the hexahistidine tag and an antisense primer annealing with the 5 C-terminal amino acids of G s␣ , the stop codon, and an XbaI site. In PCR 4, the products of PCRs 3A and 3B annealed in the hexahistidine region, and the sense primer of PCR 3A and the antisense primer of PCR 3B were used. In this way, a fragment encoding the C-terminal portion of the hH 2 R, a hexahistidine tag, G s␣S , a stop codon and an XbaI site was created. This fragment was digested with EcoRV and XbaI and cloned into pGEM-3Z-SFhH 2 R digested with EcoRV and XbaI. In this way, the full-length cDNA for hH 2 R-G s␣S was created. pGEM-3Z-SF-hH 2 R-G s␣S was digested with NcoI and XbaI to recover the fusion protein cDNA and cloned into the baculovirus transfer vector pVL 1392-SF-␤ 2 AR-G i␣2 digested with NcoI and XbaI. PCR-generated DNA sequences were confirmed by extensive restriction enzyme analysis and enzymatic sequencing.
Construction of FLAG Epitope-and Hexahistidine-Tagged cDNA for gpH 2 R-G s␣S . The strategy for creation of gpH 2 R-G s␣S cDNA was analogous to the strategy for creation of hH 2 R-G s␣S cDNA. In PCR 1A, the DNA sequence of the N-terminal portion of gpH 2 R was amplified using pGEM4Z-gpH 2 R as template. The sense primer annealed with the first 20 bp of the 5Ј-end of the gpH 2 R and included the last 8 bp of the SF in its 5Ј-extension. The antisense primer encoded the sequence CTCATGGGAGTTGTGGCTAGCGAGCCTG-CAGCAGAAGAGC to create a silent mutation yielding a new NheI site. In PCR 1B, the sequence of the C-terminal portion of gpH 2 R was amplified using pGEM4Z-gpH 2 R as template. The sense primer encoded the sequence GCTCTTCTGCTGCAGGCTCGCTAGCCA-CAACTCCCATGAG to create the new NheI site. The antisense primer encoded the five C-terminal amino acids of the gpH 2 R, a hexahistidine tag, the stop codon, and an XbaI site. In PCR 2, the products of PCRs 1A and 1B annealed in the region encoding the newly created NheI site. In PCR 2, the sense primer of PCR 1A and the antisense primer of PCR 1B were used. In this way, a fragment encoding the signal sequence, the FLAG epitope, gpH 2 R cDNA with a new NheI site, and a hexahistidine tag followed by an XbaI site was obtained. This fragment was digested with NcoI and XbaI and cloned into pGEM-3Z-SF-human formyl peptide receptor-6His digested with NcoI and XbaI. In PCR 3A, the C-terminal portion of the gpH 2 R was amplified using pGEM-3Z-SF-gpH 2 R as template, a sense primer annealing 5Ј of the newly created NheI site, and an antisense primer annealing with the hexahistidine tag. In PCR 3B, the sequence of G s␣S was amplified, using pGEM-3Z-SF-␤ 2 AR-G s␣S as tem- Fig. 2 . Comparison of the amino acid sequences of hH 2 R and gpH 2 R. The amino acid sequences of the cloned hH 2 R (Gantz et al., 1991) and gpH 2 R (Traiffort et al., 1995) are given in the one-letter code. Dots in the gpH 2 R sequence indicate identity with hH 2 R. TM domains are shown in bold. Amino acids shown in green in TM3 and TM5 represent the interaction sites of HIS with the H 2 R (Gantz et al., 1992; Nederkoorn et al., 1996) . Amino acids shown in black in the gpH 2 R sequence represent conservative exchanges. Amino acids shown in red in the gpH 2 R sequence represent nonconservative exchanges. The arrow indicates the cleavage site of KpnI, present in the cDNA of both gpH 2 R and hH 2 R. The KpnI site allowed us to construct reciprocal hH 2 R/gpH 2 R chimeras (see Fig. 10 ). N-term, extracellular N-terminal domain of H 2 Rs; C-term, intracellular C-terminal domain of H 2 Rs.; i1, i2, and i3; 1st, 2nd, and 3rd intracellular loop, respectively; e1, e2, and e3, 1st, 2nd, and 3rd extracellular loop, respectively; TM1-7, transmembrane domains 1-7.
plate, a sense primer annealing with the hexahistidine tag, and an antisense primer annealing with the 5 C-terminal amino acids of G s␣ , the stop codon, and an XbaI site. In PCR 4, the products of PCRs 3A and 3B annealed in the hexahistidine region, and the sense primer of PCR 3A and the antisense primer of PCR 3B were used. In this way, a fragment encoding the C-terminal portion of the gpH 2 R, a hexahistidine tag, G s␣S , a stop codon, and an XbaI site was created. This fragment was digested with NheI and XbaI and cloned into pGEM-3Z-SFgpH 2 R digested with NheI and XbaI. In this way, the full-length cDNA for gpH 2 R-G s␣S was created. pGEM-3Z-SF-hH 2 R-G s␣S was digested with NcoI and XbaI to recover the fusion protein cDNA and cloned into the baculovirus transfer vector pVL 1392-SF-␤ 2 AR-G i␣2 digested with NcoI and XbaI. PCR-generated DNA sequences were confirmed by extensive restriction enzyme analysis and enzymatic sequencing.
Construction of the cDNA for hH 2 R-A271D-G s␣S . The Ala-271 3 Asp-271 exchange in hH 2 R was generated by sequential overlapextension PCRs. In PCR 1A, the DNA sequence of the N-terminal portion of hH 2 R was amplified using pGEM-3Z-SF-hH 2 R-G s␣S as a template. The sense primer annealed with the first 18 bp of the 5Ј end of hH 2 R and included the last 18 bp of the SF in its 5Ј extension. The antisense primer encoded the sequence CAGAACGATATCT-TCTAACACCTCATTGATGGCATC to generate the Ala-271 3 Asp-271 exchange and a new EcoRV site at the position of the mutated amino acid. In PCR 1B, the DNA sequence of the C-terminal portion of the hH 2 R and the entire sequence of G s␣ s was amplified using pGEM-3Z-SF-hH 2 R-G s␣S as a template. The sense primer encoded the sequence GTTAGAAGATATCGTTCTGTGGCTGGGCTATGC-CAAC to generate the Ala-271 3 Asp-271 exchange and a new EcoRV site at the position of the mutated amino acid. The antisense primer encoded the five C-terminal amino acids of G s␣ , the stop codon and an XbaI site. In PCR 2, the products of PCR 1A and 1B annealed in the region encoding the newly created Ala-271 3 Asp-271 exchange and the EcoRV site. In the PCR 2, the sense primer of PCR 1A and the antisense primer of PCR 1B were used. In this way, a fragment encoding the entire hH 2 R-A271D-G s␣S fusion protein was created. This fragment was digested with EcoRI and NcoI and cloned into pGEM-3Z-SF-hH 2 R-G s␣S digested with EcoRI and NcoI. pGEM-3Z-SF-hH 2 R-A271D-G s␣S was digested with SacI and EcoN I and cloned into the baculovirus transfer vector pVL 1392-SF-hH 2 R-G s␣S digested with SacI and EcoN I. PCR-generated DNA sequences were confirmed by extensive restriction enzyme analysis and enzymatic sequencing.
Construction of the cDNAs for NgpChH 2 R-G s␣S and NhCgpH 2 R-G s␣S . For construction of hH 2 R/gpH 2 R chimeras, we took advantage of the KpnI site present at the same position of the cDNAs of both receptors. KpnI cleaves hH 2 R-and gpH 2 R cDNA in the center of the second intracellular loop (Fig. 2) . pGEM-3Z-SFhH 2 R-G s␣S and pGEM-3Z-SF-gpH 2 R-G s␣S were digested with KpnI and XbaI so that the C-terminal halves of H 2 Rs and the fused G s␣S were cut out. The fragments obtained were reciprocally cloned back into pGEM-3Z-SF-hH 2 R-G s␣S and pGEM-3Z-SF-gpH 2 R-G s␣S . As a result of this exchange, we created pGEM-3Z-SF-NgpChH 2 R-G s␣S and pGEM-3Z-SF-NhCgpH 2 R-G s␣S . These plasmids were digested with NcoI and XbaI and cloned into the baculovirus transfer vector pVL 1392-SF-gpH 2 R-G s␣S digested with NcoI and XbaI. The chimeric H 2 R-G s␣S DNA sequences were confirmed by extensive restriction enzyme analysis.
Generation of Recombinant Baculoviruses, Cell Culture and Membrane Preparation. Recombinant baculoviruses encoding the H 2 R-G s␣ fusion proteins were generated in Sf9 cells using the BaculoGOLD transfection kit (BD PharMingen, San Diego, CA) according to the manufacturer's instructions. After initial transfection, high-titer virus stocks were generated by two sequential virus amplifications. Sf9 cells were cultured in 250-ml disposable Erlenmeyer flasks at 28°C under rotation at 125 rpm in SF 900 II medium (Invitrogen, Carlsbad, CA) supplemented with 5% (v/v) fetal calf serum (BioWhittaker, Walkersville, MD) and 0.1 mg/ml gentamicin (BioWhittaker). Cells were maintained at a density of 0.5 to 6.0 ϫ 10 6 cells/ml. For infection, cells were sedimented by centrifugation and suspended in fresh medium. Cells were seeded at 3.0 ϫ 10 6 cells/ml and infected with a 1:100 dilution of high-titer baculovirus stocks encoding H 2 R-G s␣S fusion proteins. Cells were cultured for 48 h before membrane preparation. Sf9 membranes were prepared as described previously (Seifert et al., 1998a) , using 1 mM EDTA, 0.2 mM phenylmethylsulfonyl fluoride, 10 g/ml benzamidine, and 10 g/ml leupeptin as protease inhibitors. Membranes were suspended in binding buffer (12.5 mM MgCl 2 , 1 mM EDTA and 75 mM Tris/HCl, pH 7.4) and stored at Ϫ80°C until use.
Receptor 35 S]GTP␥S by filtration through GF/C filters, followed by three washes with 2 ml of binding buffer (4°C). Filterbound radioactivity was determined by liquid scintillation counting. The experimental conditions chosen ensured that no more than 10% of the total amount of [ 35 S]GTP␥S added was bound to filters. Steady-State GTPase Activity Assay. Membranes were thawed, sedimented, and resuspended in 10 mM Tris/HCl, pH 7.4. Assay tubes contained Sf9 membranes expressing H 2 R-G s␣ fusion proteins (10 g of protein/tube), 1.0 mM MgCl 2 , 0.1 mM EDTA, 0.1 mM ATP, 100 nM GTP, 1 mM adenylyl imidodiphosphate, 5 mM creatine phosphate, 40 g of creatine kinase, and 0.2% (w/v) bovine serum albumin in 50 mM Tris/HCl, pH 7.4, and H 2 R ligands at various concentrations. Reaction mixtures (80 l) were incubated for 3 min at 25°C before the addition of 20 l of [␥-32 P]GTP (0.2-0.5 Ci/tube). All stock and work dilutions of [␥- 32 P]GTP were prepared in 20 mM Tris/HCl, pH 7.4. Reactions were conducted for 20 min at 25°C. Preliminary studies under basal conditions and with HIS, IMP, and ARP showed that under these conditions, GTP hydrolysis was linear. Reactions were terminated by the addition of 900 l of slurry consisting of 5% (w/v) activated charcoal and 50 mM NaH 2 PO 4 , pH 2.0. Charcoal absorbs nucleotides but not P i . Charcoalquenched reaction mixtures were centrifuged for 15 min at room temperature at 15,000g. Seven hundred microliters of the supernatant fluid of reaction mixtures were removed, and 32 P i was determined by liquid scintillation counting. Enzyme activities were corrected for spontaneous degradation of [␥-
32 P]GTP. Spontaneous
Interaction of H 2 -Receptor Species Isoforms with Guanidines
[␥-32 P]GTP degradation was determined in tubes containing all of the above described components plus a very high concentration of unlabeled GTP (1 mM) that, by competition with [␥- 32 P]GTP, prevents [␥- 32 P]GTP hydrolysis by enzymatic activities present in Sf9 membranes. Spontaneous [␥- 32 P]GTP degradation was Ͻ1% of the total amount of radioactivity added using 20 mM Tris/HCl, pH 7.4, as solvent for [␥- 32 P]GTP. The experimental conditions chosen ensured that not more than 10% of the total amount of [␥-32 P]GTP added was converted to 32 P i . SDS-PAGE and Immunoblot Analysis. Membrane proteins were separated on SDS polyacrylamide gels containing 8% (w/v) acrylamide. Proteins were then transferred onto Immobilon-P transfer membranes (Millipore, Bedford, MA). Membranes were reacted with M1 antibody or anti-G s␣ Ig (1:1000 each). Immunoreactive bands were visualized by sheep anti-mouse IgG (M1 antibody) and donkey anti-rabbit IgG (anti-G s␣ Ig), respectively, coupled to peroxidase, using o-dianisidine and H 2 O 2 as substrates.
Molecular Modeling. Models of the seven TM helices were taken from the PDB bovine rhodopsin file 1f88 (Palczewski et al., 2000) . The starting structure of gpH 2 R TM domains was constructed from a multiple sequence-alignment of bovine rhodopsin with h␤ 2 AR (Palczewski et al., 2000) , gpH 1 R, hH 2 R, and gpH 2 R (Gantz et al., 1991; Traiffort et al., 1995; Hill et al., 1997) . The resulting TM helices in hH 2 R and gpH 2 R are highlighted in bold (Fig. 2) . First, the model was roughly minimized by the steepest descent method to remove bad contacts due to the mutated residues. In the first 100 steps, the backbone was fixed. Energy calculations were based on the Kollman all-atom force field (Kollman charges, distant dependent dielectricity constant of 4). Then IMP (5) and ARP (8) were manually docked into the model in a conformation suggested to be active from 3D QSAR results Buschauer, 1998, 1999) . The selection of amino acids interacting with the imidazolylpropylguanidine moiety based on studies with hH 2 R (Gantz et al., 1992) , h␤ 2 AR (Wieland et al., 1996; Isogaya et al., 1999) , and hH 1 R (Wieland et al., 1999) mutants. The docking with respect to TM 6 and 7 was only roughly suggested by seeking a pocket near the "hot" region around Asp-271 that may accommodate the imidazole and the pyridine moiety of IMP and ARP, respectively. Kollman all-atom types were assigned to IMP and ARP by analogy, including definition of the new atom type F (fluorine). Missing parameters (e.g., for bonds CAONB, CCOCC, FOCA, and a number of bond angles) were derived from similar types or from the Tripos force field. As hydrogen bonding parameters for F-H3, the respective values for O and N were assigned. Both ligands were provided with Gasteiger-Hueckel charges. The complexes were fully minimized (distant dependent dielectricity constant of 1) without constraints by the Powell method down to an RMS gradient of less than 0.05. All calculations were performed with SYBYL 6.7 (Tripos, St. Louis, MO) on an SGI Octane workstation (SGI, Mountain View, CA)
Miscellaneous. Protein concentrations were determined using the DC protein assay kit (Bio-Rad, Hercules, CA). All analyses of experimental data were performed with the Prism III program (GraphPad Software, San Diego, CA).
Results and Discussion
Immunological Detection of hH 2 R-G s␣S and gpH 2 R-G s␣S in Sf9 Cell Membranes. Monomeric nonfused H 2 R expressed in Sf9 cells migrates as ϳ33-kDa band in SDS-PAGE (Fukushima et al., 1997) , and the apparent molecular mass of G s␣S is ϳ45 kDa. Thus, the molecular mass of H 2 R-G s␣S fusion proteins was expected to be ϳ78 kDa. In fact, the anti-FLAG Ig detected a ϳ78-kDa band in immunoblots (Fig.  3) . The intensities of immunologically detected bands in membranes expressing hH 2 R-G s␣S and gpH 2 R-G s␣S were similar to the band intensities in membranes expressing ␤ 2 AR-G s␣L fusion protein at 7.0 pmol/mg as determined by [ 3 H]DHA saturation binding. The ϳ44-kDa band in membranes expressing ␤ 2 AR-G s␣L represents a degradation product of the fusion protein that was generated as the result of incidental freeze/thaw cycles. The membranes expressing H 2 R-G s␣S did not undergo such cycles, and accordingly, we did not observe degradation products. In membranes expressing hH 2 R-G s␣S and, to a much lesser extent, in membranes expressing gpH 2 R-G s␣S , we also observed ϳ160-kDa bands. The H 2 R is known to form homodimers (Fukushima et al., 1997) , and thus the ϳ160-kDa bands most probably represent H 2 R-G s␣S fusion protein homodimers.
[ 3 H]DHA saturation binding) and H 2 R-G s␣ fusion proteins were separated by SDS-PAGE using a gel that contained 8% (w/v) acrylamide. Fusion proteins were probed with the anti-FLAG Ig (M1 antibody). Each membrane preparation was analyzed in three different amounts (25, 50, and 100 g of protein, respectively, from left to right). Numbers on the left of the immunoblot indicate molecular masses of marker proteins. Shown is the horseradish peroxidasereacted Immobilon P membrane of a representative gel. Similar results were obtained with four other membrane preparations of hH 2 R-G s␣S and gpH 2 R-G s␣S each.
determination of the kinetics of specific [ 3 H]TIO binding was possible (Fig. 4) (Hill et al., 1997) .
Similar Antagonist Potencies at hH 2 R-G s␣S and gpH 2 R-G s␣S Expressed in Sf9 Cell Membranes and Evidence that RAN and APT Differentially Stabilize an Inactive Conformation in H 2 R Species Isoforms. In GPCR-G ␣ fusion proteins, the GTPase assay is a highly sensitive method to determine ligand potencies and efficacies Milligan, 2000) . GTP hydrolysis in Sf9 membranes expressing H 2 R-G s␣S fusion proteins was stimulated with HIS at a submaximally effective concentration, and the HIS-stimulated GTP hydrolysis was inhibited by H 2 R antagonists of various chemical classes. The K B values for CIM (14), RAN (15), ZOL (16), TIO (17), FAM (18), and APT (19) did not vary by more than a factor of 2 between hH 2 R-G s␣S and gpH 2 R-G s␣S (Table 1) . We correlated pK B values of antagonists at hH 2 R-G s␣S versus gpH 2 R-G s␣S . If the antagonist-affinities of hH 2 R-G s␣S and gpH 2 R-G s␣S were identical, we would expect a linear correlation with a slope of 1.00 that follows the dotted line in Fig. 5A . Indeed, we obtained a highly significant correlation with a slope of 0.98 close to the theoretical curve (Fig. 5A) , indicating that the antagonist-binding properties of hH 2 R-G s␣S and gpH 2 R-G s␣S are very similar. This is an important finding, because for other GPCR species isoforms, including the H 3 R, differences in antagonist-binding properties were observed (Kopin et al., 2000; Ligneau et al., 2000; Lovenberg et al., 2000) .
Previous studies had shown that the hH 2 R is constitutively active (i.e., H 2 R antagonists decrease the activity of the agonist-free hH 2 R) (Alewijnse et al., 1998) . In fact, RAN (15) had a consistent inverse agonist effect at hH 2 R-G s␣S (Table  1) . APT (19), which had not been studied in this respect previously, was a much more efficient inverse agonist than RAN (15) at hH 2 R-G s␣S . At gpH 2 R-G s␣S , RAN showed the greatest inverse agonist effect among the antagonists studied, and the effect of RAN at gpH 2 R-G s␣S was also significantly greater than at hH 2 R-G s␣S . Conversely, APT was considerably more efficient as an inverse agonist at hH 2 R-G s␣S than at gpH 2 R-G s␣S . These data show that RAN and APT differentially stabilize an inactive conformation in hH 2 R and gpH 2 R. In support of the hypothesis that different H 2 R antagonists stabilize unique conformations in H 2 Rs from different species is the finding that at the rat H 2 R, burimamide is a neutral antagonist, whereas at hH 2 R, it is a partial agonist (Alewijnse et al., 1998) .
The absolute inverse agonist activities of APT at hH 2 R-G s␣S and of RAN at gpH 2 R-G s␣S , respectively, were similar, indicating that both GPCRs exhibit a similar degree of constitutive activity. In comparison, the rat H 2 R is less constitutively active than hH 2 R (Alewijnse et al., 1998 ). These data show that H 2 R species isoforms differ from each other in their constitutive activity. Differences in constitutive activity among GPCR species isoforms are not restricted to the H 2 R (Kopin et al., 2000) . We also noted that, except for RAN (15) and APT (19), the inverse agonist effect of each individual antagonist was quite variable (Table 1) . This variability does not reflect insensitivity of the GTPase assay. Rather, we assume that in our system, CIM (14), ZOL (16), TIO (17), and FAM (18) casually act as neutral antagonists or inverse agonists at H 2 Rs, resulting in considerable data variability. Stochastic actions of weak inverse agonists were also reported for the ␤ 2 AR (Chidiac et al., 1996) . Another factor that could have contributed to the relatively small inverse agonist effects of RAN and FAM at H 2 R in this study relative to a previous study (Alewijnse et al., 1998) could be that we studied coupling of H 2 Rs to G s␣S and not G s␣L (see Experimental Procedures). Specifically, it is known that G s␣L confers the properties of constitutive activity to the ␤ 2 AR; i.e., G s␣L increases inverse agonists effects, whereas G s␣S does not have these effects (Seifert et al., 1998b ). Thus, it is possible that in the Chinese hamster ovary cells studied by Alewijnse et al. (1998) R. We determined the efficacies and potencies of the small H 2 R agonists 1 to 4 and of the larger H 2 R agonists 5 to 13 in the GTPase assay ( Table 2 ). The efficacies of HIS (1), DIM (2), AMT (3), and BET (4) were similar at hH 2 R-G s␣S and gpH 2 R-G s␣S , respectively. In contrast, the efficacies of the guanidines 5 to 13 at hH 2 R-G s␣S were all significantly lower than at gpH 2 R-G s␣S . The differences in efficacy were most prominent for BU-E-43 (7), BU-E-48 (10), and D281 (13). Specifically, elongation of the alkyl chain between the guanidino group and the phenyl ring (6 3 7) and introduction of a bulky Br atom (6 3 10) or of multiple Cl atoms into the phenyl ring (12 3 13) had pronounced negative effects on agonist efficacy at hH 2 R-G s␣S but not at gpH 2 R-G s␣S . Accordingly, the slope of the correlation of the efficacies of agonists at hH 2 R-G s␣S and gpH 2 R-G s␣S was very shallow, and the theoretical curve assuming pharmacological identity of H 2 R species isoforms was not approached within the data interval (Fig. 6A) . Particularly informative is the comparison of the efficacies of BET (4) and guanidines 8 to 11. At hH 2 R-G s␣S , these compounds possess efficacies of 0.73 to 0.87, but only guanidines have increased efficacies at gpH 2 R-G s␣S (Table 2) . Taken together, these results indicate that the hH 2 R-G s␣S and gpH 2 R-G s␣S conformations stabilized by one of the small agonists 1 to 4 similarly promote GDP/GTP exchange. In contrast, the guanidines 5 to 13 stabilize a hH 2 R-G s␣S conformation considerably less efficient for GDP/GTP exchange than the corresponding gpH 2 R-G s␣S conformation.
The potencies of small agonists (1-4) differed by not more than a factor of 2 between hH 2 R-G s␣S and gpH 2 R-G s␣S ( Table  2 ). The correlation of the pD 2 values of compounds 1 to 4 at both H 2 R-G s␣S was highly significant with a slope close to the theoretical curve assuming pharmacological identity of H 2 R species isoforms (Fig. 5B) . Except for BU-E-43 (7), the potencies of guanidines were all significantly lower at hH 2 R-G s␣S than at gpH 2 R-G s␣S . Differences in potency between hH 2 R-G s␣S and gpH 2 R-G s␣S were particularly large for BU-E-75 (11) (6.6-fold), BU-E-42 (6) (6.0-fold), and IMP (5) (5.0-fold).
TABLE 1
Potencies and inverse agonist efficacies of antagonists at hH 2 R-G s␣S and gpH 2 R-G s␣S expressed in Sf9 cell membranes K B values for hH 2 R-G s␣S and gpH 2 R-G s␣S were determined in the GTPase assay. GTP hydrolysis was determined as described under Experimental Procedures. Reaction mixtures contained Sf9 membranes expressing fusion proteins, 1 M HIS as agonist and antagonists at concentrations from 1 nM to 100 M to generate saturated competition curves. Competition curves were analyzed by nonlinear regression. To determine the inverse agonist efficacies of antagonists (Inv. Ago. Eff.), the effects of antagonists at a fixed concentration (10 M) on basal GTPase activity were assessed and referred to the stimulatory effect of 100 M HIS (ϭ 1.00). Typical basal GTPase activities ranged between ϳ1 and 2 pmol/mg/min, and typical GTPase activities stimulated by HIS (1 M) ranged between ϳ2.5 and 5.0 pmol/mg/min. Data shown are the means of four to five experiments performed in duplicate. Numbers in parentheses represent the 95% confidence intervals. The relative potency (Rel. Pot.) of CIM was set at 100, and the potencies of other antagonists were measured against this value to facilitate comparison of antagonist potencies in the various systems. The effects of compounds at hH 2 R-G s␣S were compared with the corresponding effects of compounds at gpH 2 R-G s␣S using the t test. The slope of the correlation between the pD 2 values of guanidines at hH 2 R-G s␣S and gpH 2 R-G s␣S was 0.89, and the curve nearly paralleled the theoretical curve assuming pharmacological identity of H 2 R species isoforms (Fig. 6B) , indicating a constant contribution of the guanidinoalkylaryl moiety to the ligand/GPCR interaction difference between hH 2 R and gpH 2 R. Notably, agonist potency decreased almost 3-fold at gpH 2 R-G s␣S by elongation of the alkyl chain between the guanidino group and the phenyl ring (6 3 7) (Fig. 1) , but slightly increased at hH 2 R-G s␣S . These data indicate that the guanidine binding pocket in gpH 2 R is smaller or less flexible than in hH 2 R. Taken together, guanidines stabilize an active conformation in gpH 2 R not only more efficiently but also more potently than in hH 2 R, and the structure-activity relationships for guanidines at hH 2 R and gpH 2 R are slightly different.
To further corroborate the concept of species-specific H 2 R conformations stabilized by guanidines, we competed [ 3 H]TIO binding to H 2 R-G s␣S fusion proteins with unlabeled guanidines. In the absence of guanine nucleotides, agonist, GPCR, and G-protein form a ternary complex that is characterized by high agonist affinity (Seifert et al., 1998a) . Typically, ternary complex formation is not complete; i.e., a certain fraction of GPCRs display low agonist-affinity (Seifert et al., 1998a) . Consequently, agonist-competition curves are biphasic. GTP␥S reduces agonist affinity, presumably reflecting ternary complex dissociation. However, in some cases, high-affinity agonist binding is GTP␥S-insensitive, indicative of tight GPCR/G-protein coupling (Seifert et al., 1998a) . Fig. 7 shows the [ 3 H]TIO competition curves with IMP (5), ARP (8), and BU-E-48 (10) in membranes expressing hH 2 R-G s␣S and gpH 2 R-G s␣S in the absence and presence of GTP␥S, and Table 3 provides a summary of the nonlinear regression analysis. The K l -values of guanidines 5, 8, and 10 at hH 2 R-G s␣S were all higher than at gpH 2 R-G s␣S . All K l values were much more similar to the corresponding EC 50 in the GTPase assay than the K h values (Tables 2 and 3 ). These data suggest that H 2 Rs in a conformation with low affinity for guanidines can efficiently mediate GDP/GTP exchange. An explanation for the moderate divergence between K l and EC 50 values could be that individual guanidines may interact differently with [ 3 H]TIO-bound and ligand-free H 2 R. Dissociations between agonist-affinities in binding assays and agonist potencies in functional assays have been observed for several GPCRs (Wenzel- Seifert et al., 1999; Seifert et al., 2001) , and the reader is referred to these articles and references cited therein for a detailed discussion on this topic.
At hH 2 R-G s␣S and gpH 2 R-G s␣S the IMP-competition curves in the absence of GTP␥S were monophasic (Fig. 7, A  and B) . GTP␥S shifted the IMP-competition curves at both fusion proteins to the right, indicating that despite our inability to resolve high-and low-affinity binding components, IMP still formed a ternary complex with H 2 R-G s␣S . Intriguingly, with gpH 2 R-G s␣S , the IMP-competition curve in the presence of GTP␥S was biphasic, suggesting partial stability of the ternary complex of IMP-liganded gpH 2 R with GTP␥S-liganded G s␣S . The ternary complex in the hH 2 R-G s␣S system seems to be less stable as indicated by the monophasic IMPcompetition curve in the presence of GTP␥S. ARP was highly efficient at stabilizing the ternary complex in both H 2 R-G s␣S fusion proteins (Fig. 7, C and D) . In hH 2 R-G s␣S , GTP␥S abolished ternary complex formation with ARP, as reflected by the monophasic and strongly rightward-shifted agonist competition curve (Fig. 7C) . In marked contrast, at gpH 2 R-G s␣S , GTP␥S had only a small effect on the ARP-competition curve (Fig. 7D) , indicating high stability of the ternary complex in the presence of GTP␥S-liganded G s␣S . Similar to ARP, the binding of BU-E-48 (10) at hH 2 R-G s␣S was highly GTP␥S-sensitive, and at gpH 2 R-G s␣S it was largely GTP␥S-insensitive (Fig. 7, E and F) . Collectively, these data indicate that the conformations of gpH 2 R stabilized by guanidines interact more tightly with G s␣S than the corresponding conformations of hH 2 R. Because of this different GPCR/G-protein interaction, guanidines promote steady-state GDP/GTP exchange through gpH 2 R more efficiently than through hH 2 R (Fig. 6 and Table 2).   TABLE 2 Agonist efficacies and potencies at hH 2 R-G s␣S and gpH 2 R-G s␣S expressed in Sf9 cell membranes Potencies and efficacies of ligands at hH 2 R-G s␣S and gpH 2 R-G s␣S were determined in the GTPase assay. GTP hydrolysis was determined as described under Experimental Procedures. Reaction mixtures contained Sf9 membranes expressing fusion proteins and agonists at concentrations from 1 nM to 1 mM as appropriate to generate saturated concentration/response curves. Curves were analyzed by nonlinear regression. Typical basal GTPase activities ranged between ϳ1 and 2 pmol/mg/min, and typical GTPase activities stimulated by HIS (100 M) ranged between ϳ4 and 8 pmol/mg/min. To calculate agonist efficacies, the maximum stimulatory effect of HIS was set at 1.00, and the stimulatory effects of other agonists were referred to this value. Data shown are the means Ϯ SD of four to six experiments performed in duplicate. The relative potency (Rel. Pot.) of HIS was set at 100, and the potencies of other agonists were referred to this value to facilitate comparison of agonist potencies with hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣S , and NhCgpH 2 R-G s␣S (Table 4) . Efficacies and potencies, respectively, of ligands at hH 2 R-G s␣S were compared with the corresponding parameters at gpH 2 R-G s␣S using the t test. (Palczewski et al., 2000) has improved the reliability of GPCR models with bound ligands. To elucidate the structural basis for the differences in interactions of guanidines with H 2 R species isoforms, we built three-dimensional models of the seven TM helices of gpH 2 R starting from the PDB rhodopsin file 1f88 and using the alignment with the ␤ 2 AR (Palczewski et al., 2000) . Additionally, our previous 3D QSAR data obtained by comparative molecular field analysis, correlating pD 2 values of guanidines at gpH 2 R-atrium with electrostatic and steric field variables, were considered Buschauer, 1998, 1999) , in particular for defining the conformation and superposition of structures.
Figs. 8 and 9 show the putative binding of IMP (5) and ARP (8), respectively, to gpH 2 R. Presumably, the imidazolylpropylguanidine moiety binds to H 2 R like HIS (1). Studies with H 2 R mutants proved an ionic interaction of the protonated amino group with Asp-98 (TM3) (see also Fig. 2) (Gantz et al., 1992) . The second and third site of the widely accepted threepoint model for biogenic amine/GPCR interaction could principally be formed by the couples Asp-186/Thr-190 (Gantz et al., 1992) or Tyr-182/Asp-186 in TM5 (Nederkoorn et al., 1996) . Based on a pure ␣-helical TM5, the proposed two hydrogen bonds of the imidazole ring with H 2 R are only possible with Tyr-182 and Asp-186. This assumption is also in agreement with a pH-dependent model of H 2 R activation that suggests tautomerization of the imidazole into the N -H form caused by neutralization of HIS upon binding and accompanied by proton transfers from Tyr-182 to N and from N to Asp-186, respectively (Giraldo, 1999) . Interactions of nontautomeric agonists with H 2 R are compatible with this model, too. Asn-293 of the ␤ 2 AR (Wieland et al., 1996) and Phe-436 of the H 1 R (Wieland et al., 1999) have been suggested to interact with the ␤-OH group of epinephrine and with the imidazolylethyl side chain of HIS, respectively. The corresponding residue in TM6 of the H 2 R, Phe-254, is near imidazolylpropyl side chain only if agonists do not deeply penetrate into the GPCR core. The selected orientation of the guanidines in Figs. 8 and 9 , therefore, is in agreement with our present knowledge on biogenic amine/GPCR interactions. Disregarding sequence differences deeply within the GPCR core, amino acid exchanges between hH 2 R and gpH 2 R occur only on the top of TM1 and TM7. Direct IMP-and ARP-TM1 interaction is impossible. However, the minimized gpH 2 R models consistently result in an interhelical TM1-TM7 Hbond between Tyr-17 (hH 2 R: Cys-17) and Asp-271. In TM7, there are three amino acid differences between hH 2 R and gpH 2 R (Leu-269 3 Phe-269, Ala-271 3 Asp-271, and Ile-272 3 Val-272) (Fig. 2) . With our rhodopsin-based alignment of TM7, only Asp-271 is capable of directly participating in Fig. 6 . Relations between efficacies and potencies of guanidines at hH 2 R-G s␣S , hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣S and NhCgpH 2 R-G s␣S , respectively, versus gpH 2 R-G s␣S . Agonist efficacies were taken from Tables 2  and 4 , and pD 2 values were derived from the EC 50 values shown in Tables  2 and 4 . Solid lines represent the actual correlations obtained. Dashed lines represent the 95% confidence intervals of the correlations. The straight dotted lines represent the theoretical correlations that would have been obtained if efficacies and pD 2 values, respectively, had been identical in the two systems compared with each other. The theoretical curves have a slope of 1.00. A, correlation of efficacies of agonists 5 to 13 at hH 2 R-G s␣S versus gpH 2 R-G s␣S . Slope, 0.41 Ϯ 0.10; r 2 , 0.72; p ϭ 0.0038 (significant). B, correlation of pD 2 values for agonists 5 to 13 at hH 2 R-G s␣S versus gpH 2 R-G s␣S . Slope, 0.89 Ϯ 0.32; r 2 , 0.53; p ϭ 0.0270 (significant). C, correlation of efficacies of agonists 5 to 8, 10, 11, and 13 at hH 2 R-A271D-G s␣S versus gpH 2 R-G s␣S . Slope, 0.50 Ϯ 0.12; r 2 , 0.77; p ϭ 0.0096 (significant). D, correlation of pD 2 values for agonists 5 to 8, 10, 11, and 13 at hH 2 R-A271D-G s␣S versus gpH 2 R-G s␣S . Slope, 0.81 Ϯ 0.16; r 2 , 0.83; p ϭ 0.0041 (significant). E, correlation of efficacies of agonists 5 to 8, 10, 11, and 13 at NgpChH 2 R-G s␣S versus gpH 2 R-G s␣S . Slope, 0.34 Ϯ 0.04; r 2 , 0.94; p ϭ 0.0003 (significant). F, correlation of pD 2 values for agonists 5 to 8, 10, 11, and 13 at NgpChH 2 R-G s␣S versus gpH 2 R-G s␣S . Slope, 0.67 Ϯ 1.12; r 2 , 0.07; p ϭ 0.57 (not significant). G, correlation of efficacies of agonists 5 to 8, 10, 11, and 13 at NhCgpH 2 R-G s␣S versus gpH 2 R-G s␣S . Slope, 0.36 Ϯ 0.06; r 2 , 0.88; p ϭ 0.0015 (significant). H, correlation of pD 2 values for agonists 5 to 8, 10, 11, and 13 at NhCgpH 2 R-G s␣S versus gpH 2 R-G s␣S . Slope, 0.73 Ϯ 0.28; r 2 , 0.58; p ϭ 0.0471 (significant).
ligand binding. Intriguingly, the Ala-2713Asp-271 switch is the only nonconserved amino acid exchange between hH 2 R and gpH 2 R in TM7. The model in Fig. 8 suggests that the preference of IMP for gpH 2 R relative to hH 2 R is caused by an H-bond of the N H function to Asp-271. For the pyridyl moiety of ARP, an ion-dipole interaction with Asp-271 is possible (Fig. 9) in agreement with our 3D QSAR results Buschauer, 1998, 1999) , indicating that a positive charge in 1219 TABLE 3 Binding properties of guanidines at hH 2 R-G s␣S and gpH 2 R-G s␣S expressed in Sf9 cell membranes Agonist competition binding was determined as described under Experimental Procedures. The data shown in Fig. 7 were analyzed by nonlinear regression for best fit to monophasic or biphasic competition curves. Data shown are the means of four to six experiments performed in duplicate. Numbers in parentheses represent the 95% confidence intervals. K h and K l designate the dissociation constants for the high-and low-affinity state of H 2 Rs, respectively. %R h indicates the percentage of high-affinity binding sites. The corresponding values obtained in the presence of GTP␥S (10 M) are referred to as K hGTP␥S , K lGTP␥S and %R hGTP␥S , respectively. If data were best fit to monophasic competition curves, data are listed under K l and K lGTP␥S , respectively. (Gantz et al., 1992) and the Tyr-182/ Asp-186 pair in TM5 (Nederkoorn et al., 1996) . Asn-293 of the ␤ 2 AR (Wieland et al., 1996) and Phe-436 of the H 1 R (Wieland et al., 1999) have been suggested to interact with the ␤-OH group of epinephrine and with the imidazolylethyl side chain of HIS, respectively. The corresponding residue of the H 2 R, Phe-254, is close to the imidazolylpropyl side chain only if agonists do not deeply penetrate into the GPCR core. Major differences in amino acid sequence between hH 2 R and gpH 2 R occur on the top of TM1 and TM7. The gpH 2 R model proposes H-bonds of Asp-271 (hH 2 R: Ala-271) in TM7 to the N hydrogen of the 5-methyl-1H-imidazol-4-yl group of IMP and to the OH group of Tyr-17 (hH 2 R: Cys-17) in TM1. Because of the different amino acid substitutions in hH 2 R, these H-bonds are not possible in this GPCR.
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the pyridyl region increases potency at gpH 2 R. Ala-271 in hH 2 R cannot take part in these H-bond and ion-dipole interactions.
To test the predictions of the 3D QSAR and computer modeling studies, we constructed hH 2 R-A271D-G s␣S in which Ala-271 is exchanged against Asp-271 (Fig. 10A) . Ad- Fig. 9 . Model of the interaction of ARP with the gpH 2 R. The carbon atoms of ARP (8) are shown in orange. Side chains and ␣-carbon atoms of the putative agonist-binding site and at the top of TM1 and TM7 are drawn. A, view into the GPCR core; B, lateral view. For description of the binding of the imidazolylpropyl moiety, see Fig. 8 . Asp-271 (hH 2 R: Ala-271) in TM7 again forms an H-bond to the OH group of Tyr-17 (hH 2 R: Cys-17) in TM1. For most favorable interaction with the H 2 R, the pyridyl-and the phenyl group must be arranged as shown. Attempts to roughly exchange the position of both rings by rotation of the propyl side chain bonds either resulted in high-energy conformations or in collision with the helices. Significantly different QSAR with respect to substituents at the phenyl ring of derivatives of ARP (8) and of unbranched phenyl as well as benzylthioalkyl compounds, respectively, suggest that the aryl or heteroaryl ring of structures such as IMP must be superimposed with the pyridyl ring of the pyridylphenylpropyl analogs. In particular, bulk is unfavorable for potency around the "pyridyl site" and allowed in meta and para position of the "phenyl site". This agrees with a model where the latter site points outside the GPCR core. The suggested binding mode of the "pyridyl site" of ARP derivatives further considers that 2-and 3-pyridylphenylpropyl structures are on average 0.3 to 0.4 pD 2 units more potent than the corresponding diphenyl analogs. The model in Fig. 9 assumes the pyridyl group of ARP to be surrounded by a pocket of the aromatic residues , where ligand bulk is restricted. Corresponding to Tyr-78, His-93 of the ␤ 2 AR is probably involved in the binding of the p-methoxy group of formoterol (Isogaya et al., 1999) . One of these hydrogen-donating aromatic residues might form an H-bond with the pyridyl nitrogen of ARP, but the model rather suggests an ion-dipole interaction of Asp-271 with a positively charged region of the pyridyl group. Studies with ␤ 2 AR mutants (Isogaya et al., 1999) point to an interaction of Tyr-308, corresponding to Glu-270 in H 2 Rs, with the arylalkyl side chain of formoterol. In the gpH 2 R model, a salt bridge between Glu-270 and Arg-257 (TM6) positions both side chains for additional interaction with the phenyl moiety of ARP. In agreement with our 3D QSAR studies, indicating favorable effects of negatively charged meta and para substituents, ion-dipole interactions or, as anticipated in the case of ARP, a FOHN H-bond with Arg-257 could be possible. The field effect of Arg-257 might additionally amplify interactions of Glu-270 with positively charged phenyl regions.
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at ASPET Journals on June 20, 2017 molpharm.aspetjournals.org ditionally, we took advantage of a KpnI site present in the cDNA of both hH 2 R and gpH 2 R (Fig. 2) . KpnI cleaves the cDNAs of hH 2 R and gpH 2 R at the same position localized in the middle of the second intracellular loop (Fig. 2) . Thus, we could readily construct chimeras in which the N-and Cterminal portions of hH 2 R and gpH 2 R were exchanged against each other (Fig. 10A) . NhCgpH 2 R-G s␣ bears Cys-17 and Asp-271, and NgpChH 2 R-G s␣ bears Tyr-17 and Ala-271. The chimeras could be used 1) to study the role of Asp-271/ Ala-271 in the interaction with guanidines and 2) to study the importance of the suggested H-bond between Tyr-17 and Asp-271 for the effects of guanidines at gpH 2 R. In hH 2 R-G s␣ , both chimeras and hH 2 R-A271D-G s␣ this interaction cannot take place anymore because either of the two amino acids is replaced (Fig. 1) .
Immunoblots with the anti-FLAG Ig showed that hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣S , and NhCgpH 2 R-G s␣S , like hH 2 R-G s␣S and gpH 2 R-G s␣S , had a molecular mass of ϳ78 kDa (Fig. 10B) . The expression levels of the membrane preparations shown in Fig. 10 were quite different, but this does not reflect intrinsic differences in the expression levels of constructs. Specifically, Fig. 3 contains immunoblots in which hH 2 R-G s␣S and gpH 2 R-G s␣S were expressed at higher levels than in those displayed in Fig. 10 , and similar data were obtained for NhCgpH 2 R-G s␣S (data not shown). Membranes with different expression levels were intentionally chosen for the immunoblot in Fig. 10 because certain features, namely the double bands of H 2 R-G s␣ fusion proteins corresponding to differently glycosylated species (Liu et al., 2001) , become much more obvious with constructs at low expression levels. The immunoblot with the anti-FLAG Ig also shows the dimers of NgpChH 2 R-G s␣S and hH 2 R-A271D-G s␣S migrating at ϳ160 kDa. The immunoblot with anti-G s␣ Ig confirmed that H 2 R-G s␣ fusion proteins migrate as a monomer of ϳ78 kDa and a dimer of ϳ160 kDa (Fig. 10C) . Three additional bands at ϳ50 to 60 kDa not identified with the anti-FLAG Ig are seen in the immunoblot with anti-G s␣ . They do not correspond to the endogenous G s␣ -like G-protein of insect cells because the anti-G s␣ Ig did not recognize an antigen in membranes from uninfected Sf9 cells (Fig. 10C) . The bands also do not represent degradation products since the immunoblot with the anti-FLAG Ig did not provide an indication (compare also with the partial degradation of ␤ 2 AR-G s␣L shown in Fig. 3) . Rather, we assume that the ϳ50-to 60-kDa proteins are atypically migrating H 2 R-G s␣ fusion proteins that, because of specific N-terminal glycosylation patterns, are recognized only by the C-terminally reacting anti-G s␣ Ig but not with the N-terminally reacting anti-FLAG Ig. Glycosylation-dependent reactions of fusion proteins with anti-FLAG Ig and anti-G s␣ Ig and atypical migrations of GPCRs in SDS-PAGE have been observed earlier (Grü newald et al., 1996; Liu et al., 2001) . Collectively, the immunoblots with the anti-FLAG Ig and anti-G s␣ Ig show that hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣S , and NhCgpH 2 R-G s␣S are expressed in Sf9 cell membranes and that the electrophoretic mobility of those fusion proteins is similar to the mobility of fusion proteins containing wild-type H 2 Rs. Table 4 summarizes the potencies and efficacies of HIS (1) and guanidines 5 to 8, 10, 11, and 13 at the GTPase of hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣S , and NhCgpH 2 R-G s␣S . Figure 6 , C-H, shows correlations of the efficacies and potencies, respectively of guanidines at hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣S and NhCgpH 2 R-G s␣S , respectively, versus gpH 2 R-G s␣S and allow direct comparison with the properties of hH 2 R-G s␣S versus gpH 2 R-G s␣S (Fig. 6, A and B) . Most strikingly, the correlation between the pD 2 values of guanidines at hH 2 R-A271D-G s␣S and gpH 2 R-G s␣S almost exactly followed the theoretical curve assuming pharmacological identity of the two fusion proteins (Fig. 6D) . Thus, the Ala-271 3 Asp-271 mutation increased the potency of hH 2 R for guanidines to the level of gpH 2 R (compare Fig. 6 , B and D, and Tables 2 and 4). These findings confirm the results of the 3D QSAR Buschauer, 1998, 1999) and modeling studies (Figs. 8 and 9 ) suggesting that the potency of guanidines is increased by ion-dipole or H-bond interactions with Asp-271. Such interactions cannot occur with Ala-271 in hH 2 R, which explains why at hH 2 R guanidines exhibit substantially lower potencies than at gpH 2 R (compare Fig. 6 , B and D).
The chimera NgpChH 2 R-G s␣S contains Ala-271 (Figs. 1 and 10A). As expected, the potencies of guanidines at NgpChH 2 R-G s␣S did not approach the theoretical curve assuming pharmacological identity of NgpChH 2 R-G s␣S and gpH 2 R-G s␣S (Fig. 6F) . Like hH 2 R-A271D-G s␣S , NhCgpH 2 R-G s␣S contains Asp-271. Thus, the potencies of guanidines at NhCgpH 2 R-G s␣S were expected to be higher than at hH 2 R-G s␣S and similar to the potencies at hH 2 R-A271D-G s␣S and gpH 2 R-G s␣S . Overall, the data fulfilled the predictions (Tables 2 and 4). As a result of the increase in guanidine potency at NhCgpH 2 R-G s␣S the correlation between the pD 2 values at NhCgpH 2 R-G s␣S versus gpH 2 R-G s␣S approached the theoretical function assuming pharmacological identity (compare Fig. 6, B and H) , but not as close as in the case of hH 2 R- Fig. 10 . Analysis of the expression of hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣ and NhCgpH 2 R-G s␣ fusion proteins in Sf9 cell membranes. A, schematic structures of hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣ and NhCgpH 2 R-G s␣ fusion proteins. For precise location of the KpnI site used for construction of chimeras, see Fig. 2 . Sf9 cell membranes expressing various H 2 R-G s␣ fusion proteins or membranes from uninfected Sf9 cells were separated by SDS-PAGE using a gel that contained 8% (w/v) acrylamide. Fusion proteins were probed with the anti-FLAG Ig (M1 antibody) (B) or the anti-G s␣ Ig (C). For each membrane preparation, 100 g of protein was applied to each lane. Numbers on the left of the immunoblots indicate molecular masses of marker proteins. Shown are the horseradish peroxidase-reacted Immobilon P membranes of representative gels. Similar results were obtained with two other membrane preparations of hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣ , and NhCgpH 2 R-G s␣ fusion proteins. A271D-G s␣S versus gpH 2 R-G s␣S (compare Figs. 6, D and H) . Such slightly reduced potencies were not unexpected, because in NhCgpH 2 R-G s␣S , there is not only the Ala-271 3 Asp-271 exchange, but also 32 additional amino acid exchanges in various regions of the C-terminal half of the GPCR (Fig. 2) . These exchanges can have multiple effects on the arrangements of TM domains and thereby partially annihilate the effect of the Ala-271 3 Asp-271 exchange on guanidine potency.
Regarding the properties of some specific agonists, it becomes obvious that elongation of the alkyl chain between the guanidino group and the phenyl ring (6 3 7) (Fig. 1) decreased agonist potency at hH 2 R-A271D-G s␣S and NhCgpH 2 R-G s␣S by ϳ4-fold (Table 4 ). This decrease in potency is similar to that observed for compounds 637 at gpH 2 R-G s␣S (Table 2) . Conversely, at NgpChH 2 R-G s␣S and hH 2 R-G s␣S the longer alkyl chain slightly increased agonist potency (Tables 2 and 4 ). These data indicate that the amino acid at position 271 of H 2 R affects the size and flexibility of the guanidine binding pocket. With Ala-271, the binding pocket is wider and more flexible and accommodates the longer (7) as well as the shorter guanidine (6). In contrast, with Asp-271, the fit of the longer guanidine (7) must be probably enforced by conformational strain.
Among all guanidines studied, the amino acid substitution at position 271 had the greatest and most consistent impact on the potency of IMP (5). Specifically, with Asp-271 the potencies of IMP were consistently ϳ5-to 7-fold higher than with Ala-271, regardless of whether fusion proteins with wild-type H 2 Rs, mutated H 2 R, or chimeric H 2 Rs were considered (Tables 2 and 4 ). For other guanidines, the impact of the amino acid substitution at position 271 was less consistent. These data indicate that the binding of IMP to H 2 R is considerably more dependent on interaction with Asp-271 than the binding of other guanidines to H 2 R. Major structural features of IMP (5) compared with the other guanidines studied (6-13) are the possibility of a H-bond to Asp-271 (see Fig. 8 ) and the absence of a phenyl branch (Fig. 1) . In the case of the guanidines 6-13, the weaker ion-dipole interaction with Asp-271 may be compensated by electrostatic interactions of the substituted phenyl group with and by better fit of the pyridyl moiety into a pocket of aromatic residues (see Fig. 9 ).
Another striking result of the studies with hH 2 R-A271-D-G s␣S , NgpChH 2 R-G s␣S , and NhCgpH 2 R-G s␣S was that the correlations of the efficacies of guanidines at the aforementioned constructs versus gpH 2 R-G s␣S remained almost unchanged (Fig. 6, A, C , E, and G), indicating that neither Asp-271 nor all 33 amino acids specific for the C-terminal half of gpH 2 R restored high efficacy of guanidines observed for gpH 2 R-G s␣S . These data demonstrate that guanidine potency and efficacy are independent H 2 R properties. Intriguingly, the models in Figs. 8 and 9 point to the existence of a H-bond between Tyr-17 and Asp-271, a couple of residues present only in gpH 2 R-G s␣S . Thus, our modeling and experimental data suggest that the Tyr-Asp H-bond stabilizes the agonistic conformation of the gpH 2 R bound to guanidines.
It was also surprising that HIS is 2-to 3.5-fold more potent at hH 2 R-A271D-G s␣S and NhCgpH 2 R-G s␣S (both with Cys-17 and Asp-271) than at gpH 2 R-G s␣S (Tables 2 and 4 ). TM1 and TM7 do not belong to the binding site of HIS, although it cannot be ruled out that an unfixed Asp side chain in a more flexible TM7 can slightly improve the association kinetics of small amines by "dynamic escorting".
Conclusions
In previous studies we observed that several guanidinetype H 2 R agonists are less potent and/or less efficient at the H 2 R of human neutrophils than at the H 2 R of the guinea pig atrium (Burde et al., 1989 (Burde et al., , 1990 Buschauer, 1989) . Taking advantage of the cloned hH 2 R and gpH 2 R (Gantz et al., 1991; Traiffort et al., 1995) and the GPCR-G ␣ fusion protein technique Milligan, 2000) we were able to analyze the coupling of hH 2 R and gpH 2 R to G s␣S under identical experimental conditions. Using this approach, we have dissected pharmacological differences between hH 2 R and gpH 2 R with respect to the inverse agonist efficacies of RAN (16) and APT (19) and the agonist potencies and efficacies of guanidines 5-13. Thus, our present data clearly show that hH 2 R and gpH 2 R possess, indeed, different pharmacological properties.
TABLE 4
Agonist efficacies and potencies at hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣S , and NhCgpH 2 R-G s␣S expressed in Sf9 cell membranes Potencies and efficacies of ligands at hH 2 R-A271D-G s␣S , NgpChH 2 R-G s␣S , and NhCgpH 2 R-G s␣S were determined in the GTPase assay. GTP hydrolysis was determined as described under Experimental Procedures. Reaction mixtures contained Sf9 membranes expressing fusion proteins and agonists at concentrations from 1 nM to 1 mM as appropriate to generate saturated concentration/response curves. Curves were analyzed by nonlinear regression. Typical basal GTPase activities ranged between ϳ1 and 2 pmol/mg/min, and typical GTPase activities stimulated by HIS (100 M) ranged between ϳ4 and 8 pmol/mg/min. To calculate agonist efficacies, the maximum stimulatory effect of HIS was set at 1.00, and the stimulatory effects of other agonists were referred to this value. Data shown are the means Ϯ S.D. of three to six experiments performed in duplicates. The relative potency (Rel. Pot.) of HIS was set at 100, and the potencies of other agonists were referred to this value to facilitate comparison of agonist potencies with hH 2 R-G s␣S and gpH 2 R-G s␣S (Table 2) .
Guanidines stabilize an active conformation in gpH 2 R more efficiently and potently than in hH 2 R. Site-directed mutagenesis studies and analysis of chimeric hH 2 R/gpH 2 R receptors confirmed computer modeling proposing that Asp-271 accounts for the high potency of guanidines. The gpH 2 R model also suggests that high guanidine efficacy depends on an H-bond between Asp-271 and Tyr-17 that is not possible in any other H 2 R-G s␣ construct studied. Thus, our data show that hH 2 R and gpH 2 R selectively interact with a single class of synthetic agonists, that high guanidine potency critically depends on interaction with a single single amino acid, and that agonist potency and efficacy are regulated independently of each other. The inverse order of potency of compounds 6 and 7 at hH 2 R and gpH 2 R, respectively, indicates that it is possible to develop guanidines with potency at hH 2 R. Such compounds may be useful for treating cardiac failure, acute myelogenous leukemia, and inflammatory diseases.
Our present study adds the H 2 R to the growing list of GPCR species isoforms that interact similarly with their endogenous ligand, but quite differently with synthetic ligands (Kopin et al., 2000; Ligneau et al., 2000; Lovenberg et al., 2000) . Many GPCR species isoforms, including the H 3 R, differ from each other primarily in antagonist pharmacology (Kopin et al., 2000; Ligneau et al., 2000; Lovenberg et al., 2000) . From a historical perspective, it is very fortunate that the pharmacological differences between hH 2 R and gpH 2 R mainly concern agonists and not antagonists (Fig. 5) . Otherwise, it would have been much more difficult if not impossible to develop potent H 2 R antagonists for treatment of gastroduodenal ulcer disease in man relying on animal models at a time when recombinant hH 2 R had not yet been available. However, for future development of potent and selective H 2 R agonists it will be crucial to analyze hH 2 R and not gpH 2 R.
